JACC: Cardiooncology

Article	Citations
Editorial Board	148
Full Issue PDF	136
Full Issue PDF	118
Full Issue PDF	114
LAG3 Blockade Expands T Cells Within Atherosclerotic Plaque	113
Priorities in Cardio-Oncology	97
Cardiovascular Safety in Oncology Clinical Trials	92
Hormonal Therapy and Cardiovascular Health	86
Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients	71
Full Issue PDF	65
To Anticoagulate or Not to Anticoagulate to Prevent Arterial Thrombosis During Systemic Cancer Therapy	63
Atrial Fibrillation in Patients With Cancer	62
Cancer Therapy and Exercise Intolerance: The Heart Is But a Part	61
Epigenomics of Cardio-Oncology	60
Balancing Promise and Evidence	58
Deep Inspiration Breath Hold in Left-Sided Breast Radiotherapy	57
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes	56
AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies	55
Full Issue PDF	54
Assessing Neurohormonal Antagonist Withdrawal in HER2+ Breast Cancer Patients With CTRCD	53
Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy	51
Moving the Pendulum for Earlier Detection of Systolic and Diastolic Dysfunction in Cancer Survivors	50
Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients	48
Cardiac Risk Stratification Before Lung Cancer Radiation	48
Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy	47

Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms	46
Frailty	44
CARDIAC, MUSCULAR, AND NEUROLOGICAL TOXICITY SECONDARY TO PEMBROLIZUMAB IN A PATIENT WITH MELANOMA	44
Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma	42
Long-Term, Implantable Event Monitoring of Patients With Wild-Type Transthyretin Cardiac Amyloidosis	39
Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis	39
Atorvastatin Does Not Attenuate Aortic Stiffening After Doxorubicin for Breast Cancer and Lymphoma (PREVENT-WF-98213)	37
Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients	36
PROPORTIONATE AND ABSOLUTE PULMONARY EMBOLISM MORTALITY IN ONCOLOGY IN THE UNITED STATES FROM 1999-2019	36
Risk for Myocardial Infarction Following 5-Fluorouracil Treatment in Patients With Gastrointestinal Cancer	34
Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD	34
Correlation of Natriuretic Peptides with Invasively Measured Intracardiac Filling Pressures in Patients With Cancer	34
Editorial Board/Officers Page	34
Cancer Immunotherapy Beyond Checkpoint Blockade	33
Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance	32
Changes in Physical Activity and Cardiovascular Disease Risk in Cancer Survivors	30
Full Issue PDF	28
Clonal Hematopoiesis in Cancer and Cardiovascular Disease	28
Editorial Board	28
Peripheral Ischemia Fuels Breast Cancer Via Myeloid-Skewed Hematopoiesis	28
Permissive Cardiotoxicity	28
Coronary Artery Calcium Scores After Prophylactic Premenopausal Bilateral Salpingo-Oophorectomy	27
TRASTUZUMAB CARDIOTOXICITY IN EARLY STAGE HER2 POSITIVE BREAST CANCER PATIENTS IN MEXICO	27
SUCCESSFUL DIAGNOSIS AND SURGICAL RESECTION OF A PULMONIC SARCOMATOID CARCINOMA LACKING PET AVIDITY OR MALIGNANT APPEARING CMR TISSUE CHARACTERISTICS	27
Endothelin-1	25
Leveling Up	25
The Association of Malignancy With Stroke and Bleeding in Atrial Fibrillation	23
Developing a Model for Cross-Institutional Educational Collaborations	22
Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity	22
Mismatch Between Preclinical Cardio-Oncology and Clinical Oncology Research	22
Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity	20
Genetic Testing in Evaluating Risk of Anthracycline Cardiomyopathy	20
Outcomes of Patients With Myeloproliferative Neoplasms Admitted With Myocardial Infarction	20
JACC: CardioOncology	20
Artificial Intelligence to Complement, Not Replace, Clinical Knowledge	20
Quality-of-Care Measures for Cardio-Oncology	20
Vascular Complications of Atrial Fibrillation in Patients With Cancer	20
The United Kingdom’s First Cardio-Oncology Service	20
Assessing Silent Cardiotoxicity in Long-Term Lymphoma Survivors Treated With Radiotherapy	19
Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction	19
Deep Inspiration Breath Hold to Reduce Cardiovascular Disease Risk for Breast Radiotherapy	19
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients With Active Cancer	19
A CHALLENGING CASE OF A LARGE RIGHT HEART MASS COMPLICATED BY COMPLETE HEART BLOCK	19
Enalapril for Preventing Cardiotoxicity After High-Dose Anthracycline Therapy in Breast Cancer and Lymphoma Patients	18
Endoplasmic Reticulum Selective Autophagy Alleviates Anthracycline-Induced Cardiotoxicity	18
Dantrolene as a Potential Strategy to Prevent Doxorubicin-Induced Cardiotoxicity	18
Cardiovascular Burden and Adverse Events in Patients With Esophageal Cancer Treated With Chemoradiation for Curative Intent	18
Full Issue PDF	17
Fluoropyrimidine Therapy in Gastrointestinal Cancer	17
Baseline Cardiac Parameters as Biomarkers of Radiation Cardiotoxicity in Lung Cancer	17

Prognosis of MPN Patients Experiencing Acute Thrombotic Events and the Potential Role of Cytoreduction	17
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia	16
Low QRS Voltages in Cardiac Amyloidosis	16
Heart Failure Readmission in Patients With ST-Segment Elevation Myocardial Infarction and Active Cancer	16
High-Sensitivity Troponin I	16
CHA2DS2-VASc Score in Cardio-Oncology	16
Diet and Prevention of Cardiovascular Disease and Cancer	16
Racial and Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Cancer Patients in the U.S.	16
Full Issue PDF	15
To Adjudicate or Not Adjudicate	15
Harnessing iPSCs to Dissect Causality in Anthracycline-Induced Cardiotoxicity	15
SEX DIFFERENCES IN ANTHRACYCLINE-TREATED CANCER SURVIVORS ASSESSED BY CARDIOVASCULAR MAGNETIC RESONANCE IMAGING	15
How to Perform Hematopoietic Stem Cell Transplantation	15
ABSTRACT WITHDRAWN	15
FULL ISSUE PDF	14
Cardiovascular Risk Assessment in Patients With Kidney Cancer	14
What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?	14
Association of Midlife Cardiovascular Health and Subsequent Change in Cardiovascular Health With Incident Cancer	14
Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness	14
Incident Myocardial Infarction, Heart Failure, and Oncologic Outcomes in Breast Cancer Survivors	14
Author Index	14
Second Malignancies and Cardiovascular Disease in Childhood Cancer Survivors	14
Cancer Therapy–Related Cardiac Dysfunction	14
A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?	13
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors	13
Detection of Subclinical Cardiovascular Disease by Cardiovascular Magnetic Resonance in Lymphoma Survivors	13
Hearts on the Minds of Oncologists	13
A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy	13
JACC: CardioOncology	12
Cardiovascular Considerations After Cancer Therapy	12
PREVALENCE OF IMPAIRED CARDIORESPIRATORY FITNESS & ITS CONTRIBUTORS IN LUNG CANCER PATIENTS PRIOR TO RADIOTHERAPY	12
PALLIATIVE RESECTION OF A CARDIAC SARCOMA	11
(Less) Time and Energy	11
Reply	11
PULMONARY VASCULAR TOXICITY WITH TYROSINE KINASE INHIBITOR THERAPY: A RARE CASE IN A CHRONIC MYELOID LEUKEMIA PATIENT	11
Evaluating Anticoagulant Strategies for Atrial Fibrillation in Patients With Cancer	11
Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors	11
Guiding Treatment With Recovered CTRCD	11
Navigating the Uncharted	11
Clinical Practice Guidelines in Cardio-Oncology	10
Reply	10
Cardiovascular Care After Cancer	10
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction	10
The Cause of Death in Patients With Cancer	10
Reply	10
Preventing Cancer Therapy–Related Cardiotoxicity	10
Full Issue PDF	10
Addressing the Overlooked	10
Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer	10
Considerations of Competing Risks Analysis in Cardio-Oncology Studies	10
The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity	10
Amyloid Cardiomyopathy	9
Reply	9
High-Sensitivity Cardiac Troponin I for Long-Term Cardiovascular Risk Stratification in a Cancer Clinic Population	9
ASYMPTOMATIC CARDIAC METASTASIS OF NEUROENDOCRINE TUMOR DIAGNOSED BY PET CT SCAN	9
Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy	9
Postural Orthostatic Tachycardia Syndrome and Orthostatic Hypotension Following Hematopoietic Stem Cell Transplantation	9
Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients	9
Editorial Board/Officers Page	9
TYROSINE KINASE INHIBITOR ASSOCIATED POLYMORPHIC VENTRICULAR TACHYCARDIA	9
A Biomarker-Based Diagnostic Model for Cardiac Dysfunction in Childhood Cancer Survivors	9
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology	9
Reply	9
ELECTROPHYSIOLOGIC PROPERTIES OF HEART BLOCK INDUCED BY IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS FROM CEMIPLIMAB	9
When Clot Is Tumor	8
Assessing STEMI Outcomes in Patients With Cancer	8
Full Issue PDF	8
Genetic Susceptibility for Anthracycline-Induced Cardiomyopathy	8
Overcoming LGBTQI+ Disparities in Cardio-Oncology	8
Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category	8
The ESC Cardio-Oncology Guidelines	8
Learning From Trials	8
Growing, Building, and Defining the Field of Cardio-Oncology for Our Patients	8
Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy	7
Genomics for Improving Heart Failure Risk Assessment in Cancer Patients	7
Reply	7
Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma	7
Reply	7
The Association of Metformin With Heart Failure in Patients With Diabetes Mellitus Receiving Anthracycline Chemotherapy	7
Cancer Diagnosis, Physical Activity, and Heart Disease Risk	7

Editorial Board	7
FIRST DOSE ORTHOSTATIC HYPOTENSION FOLLOWING DOCETAXEL AND GEMCITABINE INFUSION	7
Pumping Up the Standards	7
Cardiovascular Concerns, Cancer Treatment, and Biological and Chronological Aging in Cancer	7
Leukemia and Heart Disease	7
Reply	7
LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice	7
ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity	7
Predicting Left Ventricular Dysfunction in Childhood Cancer Survivors	7
Longitudinal Patterns of Cardiovascular Disease and Cancer Mortality in Renal Cell Carcinoma Patients by Tumor Stage	7
Cardiac Biomarkers in Patients With Suspected Amyloid (Transthyretin) Cardiomyopathy	7